A study in older healthy mice suggests that semaglutide, the active ingredient in Ozempic, may slow the aging process itself. The treatment helped the animals live longer while also improving memory, muscle function, blood sugar control, and several biological signs of aging, according to a report from ScienceDaily.
The findings are notable because the effects went beyond those achieved with calorie restriction alone. That raises the possibility that GLP-1 drugs like semaglutide could act through an independent pathway that targets aging directly, rather than simply reducing food intake or improving metabolic health.
Because the study was conducted in mice, it is not yet clear whether the same benefits would appear in humans. Still, the results add to a growing body of evidence that these drugs may have effects that go beyond diabetes and weight management, potentially opening a new avenue for aging research.